OPTINOSE
OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal "Bi-Directional Delivery" which allows drugs to be more efficiently delivered to the nasal cavity. By applying its drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices. The OptiNose delivery devices have high d... ose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a faster onset of action, greater effect with a lower dose, and reduced side effects. The company has offices in Norway and the UK.
OPTINOSE
Social Links:
Industry:
Biotechnology Medical Device Pharmaceutical
Founded:
2000-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.optinose.com
Total Employee:
101+
Status:
Active
Contact:
267-364-3500
Email Addresses:
[email protected]
Total Funding:
401.43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aprecia Pharmaceuticals
Aprecia Pharmaceuticals develops precision drug delivery systems and products.
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
FGen
FGen develops proprietary technologies and products in different biotechnological areas.
Myomo
Myomo develops devices with myoelectric prosthetic technology to restore the mobility of individuals with muscle weakness.
OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - OptiNose
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - OptiNose
Avista Capital Partners
Avista Capital Partners investment in Series D - OptiNose
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series D - OptiNose
Entrepreneurs Fund
Entrepreneurs Fund investment in Series D - OptiNose
Avista Capital Partners
Avista Capital Partners investment in Series C - OptiNose
The Entrepreneurs' Fund
The Entrepreneurs' Fund investment in Series C - OptiNose
WFD Ventures
WFD Ventures investment in Series C - OptiNose
Avista Capital Partners
Avista Capital Partners investment in Series C - OptiNose
Entrepreneurs Fund
Entrepreneurs Fund investment in Series C - OptiNose
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-03 | Optinose Announces Departure of Chief Financial Officer |
Official Site Inspections
http://www.optinose.com Semrush global rank: 2.7 M Semrush visits lastest month: 6.13 K
- Host name: 20.119.8.33
- IP address: 20.119.8.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
